Life Sciences & Biotechnology
Title : | Evaluation of Human Leukocyte Antigen Class IIDRB1 and DQB1 and Its Association with Cervical Carcinoma |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Immunology and Cancer Research |
Principal Investigator : | Dr. Mriganka Mouli Saha, College Of Medicine & JNM Hospital, Kalyani, West Bengal |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | itsmemriganka@yahoo.com |
Details
Executive Summary : | The association of human leukocyte antigen (HLA) with various autoimmune diseases has been studied well. It has been associated with evolution of carcinoma but not studied well in patients of carcinoma. On the other hand human papillomavirus (HPV) is the main causal factor of cervical cancer. The variability in host human leukocytes antigen (HLA) class II type antigens is an important variable in determining the overall cellular immune response to HPV infections. Approximately 70% of cervical cancers occur in developing countries like India. Human papillomavirus (HPV) infection appears to be involved in the development of more than 99.7% of cases. However, current evidence suggests that most HPV infections are self-limited and that only a minority of untreated cervical HPV infections progress to cervical cancer. Cellular immunity may be critical in the elimination of HPV harbouring cells. Many studies have analyzed different HLA class II type antigens in Cervical Intraepithelial Neoplasia(CIN) and cervical cancer susceptibility. It has been suggested in various studies abroad that women carrying HLA DQB1 antigen contributes to the inability to clear an HPV infection and develop cervical cancer. The objective of the present study is to investigate if HLA class II alleles are associated with persistence of infection, independently of its progression to cervical cancer. A total 100 women fulfilling the inclusion and exclusion criteria will be studied. All participants will be divided in to three groups at the entry in to the study – Control group, HPV positive group, cervical cancer group. HLA Class II genotyping of DQB1 and DRB1 will be detected by a PCR technique with the DNA extracted from the peripheral blood. |
Co-PI: | Dr. Sourav Sarkar, College Of Medicine & JNM Hospital, Kalyani, West Bengal-741235 |
Total Budget (INR): | 24,36,280 |
Organizations involved